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Abstract 
Background: The World Health Organization (WHO) has set elimination (interruption of transmission) as an end goal 
for schistosomiasis. However, there is currently little guidance on the monitoring and evaluation strategy required 
once very low prevalence levels have been reached to determine whether elimination or resurgence of the disease 
will occur after stopping mass drug administration (MDA) treatment.
Methods: We employ a stochastic individual-based model of Schistosoma mansoni transmission and MDA impact 
to determine a prevalence threshold, i.e. prevalence of infection, which can be used to determine whether elimina-
tion or resurgence will occur after stopping treatment with a given probability. Simulations are run for treatment 
programmes with varying probabilities of achieving elimination and for settings where adults harbour low to high 
burdens of infection. Prevalence is measured based on using a single Kato-Katz on two samples per individual. We 
calculate positive predictive values (PPV) using PPV ≥ 0.9 as a reliable measure corresponding to ≥ 90% certainty 
of elimination. We analyse when post-treatment surveillance should be carried out to predict elimination. We also 
determine the number of individuals across a single community (of 500–1000 individuals) that should be sampled to 
predict elimination.
Results: We find that a prevalence threshold of 1% by single Kato-Katz on two samples per individual is optimal for 
predicting elimination at two years (or later) after the last round of MDA using a sample size of 200 individuals across 
the entire community (from all ages). This holds regardless of whether the adults have a low or high burden of infec-
tion relative to school-aged children.
Conclusions: Using a prevalence threshold of 0.5% is sufficient for surveillance six months after the last round of 
MDA. However, as such a low prevalence can be difficult to measure in the field using Kato-Katz, we recommend 
using 1% two years after the last round of MDA. Higher prevalence thresholds of 2% or 5% can be used but require 
waiting over four years for post-treatment surveillance. Although, for treatment programmes where elimination is 
highly likely, these higher thresholds could be used sooner. Additionally, switching to more sensitive diagnostic tech-
niques, will allow for a higher prevalence threshold to be employed.
Keywords: Schistosomiasis, Elimination of transmission, Stochastic individual-based model, Positive predictive value, 
Prevalence threshold, Post-treatment surveillance, Monitoring and evaluation
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Background
Schistosomiasis is an intestinal or urogenital neglected 
tropical disease (NTD) caused predominantly by infec-
tion with Schistosoma mansoni, S. haematobium or S. 
japonicum. Over 200 million people require preventive 
chemotherapy (PC) for the disease across 52 endemic 
countries [1]. As school-aged children (SAC; 5–14 years 
of age) are most likely to be infected by Schistosoma 
species, PC using mass drug administration (MDA) of 
praziquantel has focused on this age group. By 2020, the 
World Health Organization (WHO) aims to increase 
coverage such that 75% of SAC at risk will be regularly 
treated in endemic countries [2]. Adults are also likely 
to be infected and in areas of high transmission, WHO 
guidelines recommend treatment of adults at risk [3]. 
Recent modelling work has highlighted the importance 
of including adults within treatment programmes, with 
coverage levels impacted by the burden of infection in 
adults relative to SAC, particularly in high prevalence 
(transmission) settings [4, 5]. Pre-school aged children 
(pre-SAC) are not presently eligible for treatment with 
praziquantel [6]. However, recent work shows that prazi-
quantel may be used on an individual diagnosis level to 
treat pre-SAC, provided the dosage is correct [7].
The WHO has set goals of morbidity control and 
elimination as a public health problem, defined by 
reaching <  5% and <  1% prevalence of heavy-intensity 
infections (eggs per gram ≥ 400) in SAC, respectively 
[3]. These goals are to be achieved using MDA with the 
treatment frequency determined by the prevalence prior 
to treatment, as recommended by the WHO [3]. Once 
prevalence of infection is less than 1% by Kato-Katz 
among SAC, the WHO currently recommends conduct-
ing serology once every two years and PC is then stopped 
if this is negative. The end goal for schistosomiasis has 
been set as elimination (interruption of transmission) to 
be reached by 2025 in the Region of the Americas, the 
Eastern Mediterranean Region, the European Region, 
the South-East Asia Region and the Western Pacific 
Region, and in selected countries of the African Region 
[3]. This is achieved by reducing the incidence of infec-
tion to zero [3]. Currently, there is a lack of appropriate 
guidance on how to determine whether elimination has 
occurred, as well as how to identify potential resurgence 
(bounce-back) after stopping treatment once very low 
prevalence levels have been reached. Hence, it is impor-
tant that the appropriate protocols, based on understand-
ing of transmission dynamics, are designed to determine 
the elimination criteria for schistosomiasis treatment. It 
is important to note that the WHO treatment guidelines 
and the 2030 WHO goals are currently under review.
As schistosome parasites reproduce sexually within 
the human host, both sexes need to be present within an 
individual host to produce fertilized eggs (maintaining 
the transmission cycle). As the prevalence of infection 
declines, the likelihood of having both sexes present in 
the same individual declines. This results in a breakpoint 
of transmission where below a critical prevalence thresh-
old, the parasites cannot reproduce frequently enough to 
maintain transmission leading to eradication of infection, 
even without ongoing treatment in the absence of fre-
quent immigration of infected individuals into a defined 
area. The optimal prevalence threshold has been defined 
for other helminth infections, such as the soil-transmit-
ted helminths [8, 9]. Here we apply similar methods for 
determining the prevalence threshold for S. mansoni. 
Notably, the lifecycle of schistosomes includes complexi-
ties, such as asexual reproduction within the intermedi-
ate snail host, which are accounted for in the model.
In this study, we provide guidance on the post-treat-
ment surveillance criteria for S. mansoni in terms of the 
prevalence threshold that is required to reliably predict 
elimination, the number of individuals that need to be 
sampled within a community, and how long after the last 
round of treatment this should be checked.
Methods
We employed a stochastic individual-based mathemati-
cal model to define the prevalence threshold, i.e. preva-
lence of infection, which needs to be reached to ensure 
that elimination will be achieved with defined probabil-
ity. The model tracks individuals within the population 
(both human hosts and their parasite populations) as 
they become infected as well as treated over time. The 
model has been previously used for the soil-transmitted 
helminths [9, 10] and has been adapted to represent S. 
mansoni transmission (parameter values in Table  1). 
The mean value of the stochastic simulations aligns with 
the predictions of an age-structured partial differential 
equation deterministic model [11]. Within the model we 
focused on a single community without migration. We 
measured prevalence using a single Kato-Katz on two 
separate stool samples per individual as the diagnos-
tic test. We used two age-profiles of infection with low 
and high burdens of infection in adults relative to SAC 
(produced by varying the age specific contact rates) and 
varying associated transmission intensities (i.e. basic 
reproductive  (R0) values; Table 1) [5, 12].
We simulated high baseline prevalence settings (≥ 50% 
SAC prevalence by Kato-Katz) and carried out annual 
treatment at high coverage levels (85% SAC + 40% adults 
and 100% SAC + 100% adults) in order to reduce preva-
lence to very low levels within 8 to 12 years. We assumed 
treatment coverage occurs at random at each round of 
MDA and that there is no systematic non-adherence. 
Notably, annual treatment of 75% SAC-only for 15 years 
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did not achieve elimination in any of these high preva-
lence settings. 1000 model iterations were run for each 
scenario and the model was pre-run for 10 years to 
achieve a stable equilibrium prior to MDA. Elimination 
was then checked at year 60 (50 years after MDA initi-
ated). The scenarios vary from low to high likelihoods 
of elimination occurring. Scenarios where elimination 
was highly unlikely (≤ 13%) or likely (≥ 89%) were not 
focused on as they were not informative for this analysis 
(scenarios shown in Table 2 and Additional file 1: Figure 
S1).
We determined the prevalence threshold that needs to 
be reached to distinguish between achievement of elimi-
nation or bounce-back by calculating positive/negative 
predictive values (PPV/NPV). The PPV is the proportion 
of eliminations detected by the threshold statistic that 
result in long-term eliminations, whereas, the NPV is 
the proportion of bounce-backs detected by the thresh-
old statistic that result in resurgence of the disease. The 
threshold statistic for this analysis is based on prevalence. 
In order to reliably predict eliminations, a high PPV is 
required. A PPV of 1 is ideal as this corresponds to 100% 
certainty of elimination. Here we regarded PPV ≥ 0.9 as 
a reliable measure corresponding to ≥ 90% certainty of 
elimination (therefore regarding PPV < 0.9 as an unreli-
able measure corresponding to < 90% certainty of elimi-
nation). PPV and NPV were calculated for Kato-Katz 
prevalence threshold values of 0.5, 1, 2 and 5% up to 
12 years after the last round of MDA to determine the 
appropriate timepoint for post-treatment surveillance 
(PPV and NPV shown in Additional file  1: Table  S1). 
Additionally, we tested these Kato-Katz prevalence 
threshold values for scenarios with low to high likeli-
hoods of elimination occurring.
We also determined the sample sizes (whilst sampling 
from the entire community across all age groups at ran-
dom) required to predict whether elimination has been 
achieved. For our single community analysis, we sam-
pled between 100 individuals up to the entire population 
Table 1 Parameter values used for Schistosoma mansoni 
Parameter Value Source
Fecundity (egg output per female worm in absence of density 
dependence)
0.34 eggs/female worm/sample [11, 23, 24]
Variation in egg counts within individuals 0.87 [23, 24]
Aggregation parameter for high baseline prevalence settings 0.24 [5, 25, 26]
Density dependence fecundity 0.0007/female worm [12, 25]
Worm lifespan 5.7 years [11, 27]
Drug efficacy 86% [28]
Low adult burden setting: age-specific contact rates for 0–5, 5–10, 
10–16, 16+ years of age
0.01, 1.2, 1, 0.02 [5, 12]
High adult burden setting: age-specific contact rates for 0–5, 5–12, 
12–20, 20+ years of age
0.01, 0.61, 1, 0.12 [5, 12]
Prevalence of infection Percentage of population having egg count threshold (or eggs per 
gram, epg) > 0
–
Prevalence of heavy-intensity infections Percentage of population having egg count threshold ≥ 16 
(epg ≥ 400 divided by 24 to convert to egg count)
[29]
Human demography Based on Uganda’s demographic profile [30, 31]
Table 2 Settings and treatment strategies used within the 
model simulations showing the likelihood of achieving 
elimination. Settings in non-bold text were not focused on in the 
analysis due to very low/high likelihood of achieving elimination. 
Mean baseline prevalence is shown for across the entire 
community (all ages). Corresponding age-specific contact rates 
for the low and high adult burden settings are shown in Table 1
Setting Annual treatment 
strategy
Programme 
length (years)
Simulations 
achieving 
elimination (%)
Low adult 
burden
(R0 = 3; mean 
baseline 
prevalence 
58%)
75% SAC-only 15 0
85% SAC + 40% 
adults
10 13
12 45
15 89
100% SAC + 100% 
adults
5 0
8 60
10 99
15 100
High adult 
burden
(R0 = 4; mean 
baseline 
prevalence 
61%)
75% SAC-only 15 0
85% SAC + 40% adults 15 0
100% SAC + 100% 
adults
10 60
15 99
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(where the population size was set at 500 or 1000 
individuals).
Results
A prevalence threshold of 0.5% by Kato-Katz is most suf-
ficient for predicting elimination six months after stop-
ping treatment with a PPV ≥ 0.9. A prevalence threshold 
of 1% can predict elimination at least two years after the 
last round of treatment (PPV ≥ 0.9). Higher prevalence 
threshold values of 2% or 5% require waiting over four 
years for post-treatment surveillance (Fig. 1). These prev-
alence threshold measures are representative of preva-
lence across the entire community (not SAC-only).
When using a 0.5% prevalence threshold, for a popula-
tion of size 500, it is sufficient to sample 100 individuals 
across all age groups two years post-treatment (Fig. 2a). 
However, when using a prevalence threshold of 1%, a 
sample size of 100 individuals is not informative as at 
least 200 individuals need to be sampled to achieve a 
PPV ≥ 0.9 (Fig. 2a, b). Similarly, a sample size of 200 indi-
viduals was reliable for larger population sizes of 1000 
individuals. These results hold regardless of whether 
there is a low or high adult burden of infection. Preva-
lence thresholds of 2% and 5% are not sufficient two years 
post-treatment as they do not achieve PPV ≥ 0.9 even if 
the entire population is sampled (Fig. 2a), we would need 
to wait over four years post-treatment for these thresh-
olds to be informative (Fig. 1).
The required prevalence threshold can be adapted 
depending on the likelihood of achieving elimination. 
For treatment programmes which are highly likely to 
achieve elimination (i.e. programmes which have main-
tained high coverage and adherence over each round of 
MDA), a higher prevalence threshold can be used, for 
example, in scenarios where ≥ 90% scenarios reach elimi-
nation, a threshold of 5% is sufficient to achieve a high 
PPV value (Fig. 3). For treatment programmes which are 
very unlikely to achieve elimination, a smaller threshold 
of 0.5% is required to achieve a high PPV value (Fig. 3). In 
the simulations presented in this paper, we have focused 
on scenarios of different  R0 values and MDA coverage 
where there is a moderate likelihood of elimination (45–
60%; Table  2). In these cases, a prevalence threshold of 
0.5 or 1% two years post-treatment gives a reliable PPV 
greater than 0.9 (Fig. 3).
Discussion
Although the WHO has set elimination as the end goal 
for schistosomiasis [3], there has been a lack of guidance 
on the criteria required for determining whether elimina-
tion or resurgence will occur after stopping treatment. 
Currently there is little guidance for programme manag-
ers on what to do once very low levels of prevalence have 
been reached. Using our modelling approach, we have 
shown that a prevalence threshold of 1% by Kato-Katz 
and a sample size of 200 individuals (in a defined com-
munity of 500 to 1000 individuals) is sufficient for pre-
dicting S. mansoni elimination two years after cessation 
of treatment (Fig. 4).
Programmatic limitations
A prevalence threshold of 0.5% is sufficient to predict 
elimination six months after stopping treatment. How-
ever, this can be difficult to measure reliably using Kato-
Katz in the field as it is a very low prevalence. Higher 
prevalence thresholds of 2% or 5% can be used but 
require waiting for over four years for post-treatment 
surveillance which may not be ideal for treatment pro-
grammes. Hence, due to such programmatic limitations, 
we recommend using a 1% prevalence threshold two 
years after stopping treatment.
A higher prevalence threshold or a smaller sample size 
could be used with lower accuracy (PPV < 0.9 i.e. less 
than 90% certainty of elimination). This approach may 
be a viable option for treatment programmes which are 
highly certain that elimination will be achieved due to 
consistently high MDA coverage and individual adher-
ence to treatment over many rounds of MDA. However, 
to accurately determine achievement of elimination with 
greater than 90% certainty, we recommend a 1% preva-
lence threshold with a sample size of 200 individuals.
Fig. 1 Positive predictive values (PPV) over time for varying Kato-Katz 
prevalence threshold values (0.5, 1, 2 and 5%) whilst sampling 
200 individuals across the entire community (population size is 
set at 500). The trends are for the high adult burden setting where 
treatment has been carried out for 100% school-aged children and 
100% adults annually for 10 years. The dashed black line is where 
the PPV is 0.9 and the grey line is where the time after stopping 
treatment is 2 years. The area shaded in red is where PPV < 0.9 and in 
green is where PPV ≥ 0.9. Corresponding PPV and negative predictive 
values (NPV) shown in Additional file 1: Table S1
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As we have focused on optimizing the PPV (PPV ≥ 0.9), 
rather than the NPV, we are more accurately identify-
ing elimination rather than resurgence. Alternatively, 
the analysis could be used to optimize NPV if predicting 
resurgence is the aim. Ideally, both PPV and NPV should 
be ≥ 0.9, and for our recommendations this holds (PPV 
and NPV shown in Additional file 1: Table S1).
Within our high baseline prevalence simulations, 
high coverage levels such as 100% SAC and 100% adult 
treatment were used in order to reduce prevalence to 
very low levels within 12 years. Lower coverage levels 
would require a longer MDA programme. In contrast, 
communities with a lower baseline prevalence would 
likely require lower coverage levels or a shorter MDA 
programme to achieve elimination.
Model limitations and future work
As programmes move from morbidity control towards 
elimination, diagnostic techniques are becoming 
increasingly important as prevalence needs to be meas-
ured at low levels. It is important to consider which 
diagnostic techniques will be used in monitoring schis-
tosomiasis infection. The traditional Kato-Katz diag-
nostic (currently recommended diagnostic by WHO 
[13]) has low sensitivity to detect infection at very low 
intensities and prevalences [14]. However, the point-of-
care circulating cathodic antigen (POC-CCA) diagnos-
tic technique performs better at detecting infection at 
low prevalence levels due to increased sensitivity [15–
17]. Within this analysis, we have used Kato-Katz as 
the diagnostic to measure prevalence. However, a more 
sensitive diagnostic test, such as POC-CCA, or using 
more than two Kato-Katz will likely allow for a higher 
prevalence threshold [18]. Future work will investigate 
how prevalence threshold and sample sizes vary for 
such diagnostics. Whilst considering diagnostics within 
monitoring and evaluation activities, the economic 
costs also need to be considered [19].
Within our analysis, the sampling has been car-
ried out at random across the community from all age 
groups. A sample size of 200 individuals has proven to 
be informative for settings where adults harbor both 
low and high burdens of infection. However, this could 
be adapted to sampling from specific age groups, e.g. 
SAC-only or SAC and adults, as this may reveal that 
sampling from adults is more important in regions 
where adults are highly infected. Previous work has 
shown that monitoring SAC and adults is important for 
determining appropriate treatment strategies, particu-
larly in high prevalence settings [5].
Schistosomiasis is a focal disease as prevalence levels 
have been shown to vary widely between communities 
on a variety of spatial scales. District-level mapping 
for estimating schistosomiasis prevalence has shown 
that sampling less children in more schools rather than 
more children in less schools increases accuracy of 
prevalence estimates whilst optimizing cost-efficiency 
[20]. Our analysis has focused on a single commu-
nity with population sizes of 500 to 1000 individuals, 
thereby assuming no immigration of infected individu-
als from neighboring communities where infection may 
persist. Future analyses will be extended to simulate 
multiple communities to capture the impact of spatial 
heterogeneity and migration. Furthermore, analyses 
will be extended to other schistosome species, such as 
S. haematobium, as well as the incorporation of risks 
posed by emerging widespread zoonotic schistosome 
species [21, 22].
Fig. 2 Positive predictive values (PPV) for varying sample sizes of 100 
to 500 individuals across the entire community (population size is set 
at 500). a For high adult burden setting using 0.5 to 5% prevalence 
threshold values 2 years post-treatment. b For three scenarios using a 
1% prevalence threshold value 2 years post-treatment. In a and b the 
dashed black line is where the PPV is 0.9 and the grey line is where 
the sample size is 200. The area shaded in red is where PPV < 0.9 and 
in green is where PPV ≥ 0.9
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Conclusions
We have found that a prevalence threshold value of 1% 
by Kato-Katz is optimal (ensuring PPV ≥ 0.9 i.e. ≥ 90% 
certainty) for predicting S. mansoni elimination at least 
two years after the last round of treatment using a sam-
ple size of 200 individuals (where the total population 
size is 500 to 1000 individuals). We hope this study pro-
vides clear guidance on the post-treatment surveillance 
which needs to be carried out when approaching elimi-
nation for schistosomiasis in a defined area.
Additional file
Additional file 1: Figure S1. Simulations achieving elimination or resur-
gence after stopping mass drug administration (50 simulations are shown 
for each scenario). a Low adult burden setting; treating 85% SAC + 40% 
adults annually for 12 years. b Low adult burden setting; treating 100% 
SAC + 100% adults annually for 8 years. c High adult burden setting; treat-
ing 100% SAC + 100% adults annually for 10 years. Table S1. Positive and 
negative predictive values (PPV and NPV) whilst sampling 200 individu-
als across the entire community (population size is 500) using single 
Kato-Katz on two samples per individual. Values are shown for high adult 
burden setting where treatment has been carried out for 100% school-
aged children and 100% adults annually for 10 years. For each prevalence 
threshold, values highlighted in blue are time points for which PPV ≥ 0.9 
and in grey are time points for which PPV < 0.9. PPV shown in Fig. 1.
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Fig. 3 Prevalence threshold value and positive predictive values 
(PPV) for treatment programmes with low (13%), moderate (45–60%) 
and high (91%) likelihoods of achieving elimination. Values are shown 
for surveillance occurring 2 years post-treatment with a sample size 
of 200 individuals (population size is set at 500)
Fig. 4 Simulations achieving elimination or bounce-back after 
stopping treatment (50 simulations are shown for a total population 
size of 500 individuals) for a high adult burden setting; treating 100% 
SAC + 100% adults annually for 10 years (10 rounds of treatment 
starting at year 0 and ending at year 9). Model recommendations 
are shown in green dashed lines where post-treatment surveillance 
is carried out 2 years after the last round of treatment using a 1% 
prevalence threshold
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